


Services Available List
2021-2022

United Kingdom
National External
Quality Assessment Service

COVID-19
Programmes
INCLUDED



Who are UK NEQAS?

Our Mission:

Improving global diagnostic testing for the benefit of patients through quality assessment and education

For over 50 years members of UK National External Quality Assessment Service (UK NEQAS) have been the world leading providers of Clinical Laboratory External Quality Assessment (EQA)/Proficiency Testing (PT) programmes. At present UK NEQAS offers over 500 different EQA/PT programmes covering over 5000 unique analytes, ensuring full coverage of all aspects of clinical laboratory testing worldwide. These programmes support the delivery of accurate and precise clinical laboratory tests on patients regardless of where they are performed. Additionally, findings from UK NEQAS programmes support the identification of best practice amongst service users and are often used to produce national and international guidelines. This promotes the implementation of best practice procedures worldwide and benefits patient care on a global scale.

The EQA/PT services offered by UK NEQAS are continually developing in response to changes in clinical laboratory requirements, and innovation is an area in which UK NEQAS has always led. This has been highlighted recently with the COVID-19 pandemic, where the UK NEQAS consortium has developed several EQA/PT programmes. UK NEQAS rapidly deployed EQA/PT programmes with some achieving accreditations to ISO 17043:2021 in just 12 weeks from conceptual development. We now have a number of programmes which cover the detection and monitoring of COVID-19 along with several educational competency programmes for staff undertaking swabbing and sample handling. These programmes are listed in this brochure on a specific COVID-19 page for ease of identification.

Our EQA/PT services have always included assessment of the 'end-to-end' process of patient investigation, including interpretation of results, either in stand-alone programmes or integrated into standard exercises. These traditional EQA/PT services are enhanced by our Pre and Post Analytical Quality Monitoring service (known as PrepQ), in which we have established a true end-to-end system, allowing laboratories to monitor pre and post analytical issues to support the requirements of ISO 15189.

UK NEQAS EQA/PT services are provided by expert centres in 11 cities around the UK, with each covering a specific area of clinical laboratory EQA/PT. These centres form the UK NEQAS Consortium, a not-for-profit company limited by guarantee and a UK Registered Charity (no: 1044013). To ensure the provision of high quality and independent EQA/PT services every UK NEQAS member centre has no commercial interests, is staffed by a dedicated team of EQA/PT specialists, operates on a strict not-for-profit basis, is accredited to ISO 17043, and operates programmes specifically designed to improve patient care.

At UK NEQAS we are committed to the provision of EQA/PT services that support the continual improvement of healthcare services by

- providing education
- facilitating clinical audit
- monitoring clinical effectiveness
- assisting in the management of risk
- generating information used for research and development

By providing EQA/PT that fulfil these requirements, members of the UK NEQAS Consortium support laboratories in the accurate and precise delivery of their services ensuring patients receive the highest quality diagnostic testing wherever in the world they may be.

The worldwide partnerships between UK NEQAS and laboratories are ultimately for the benefit of patients and we are proud to support high quality healthcare through these relationships. We realise that there is always work required to develop EQA/PT systems, we are committed to undertake this process and always welcome feedback and suggestions on how we can improve our services.

Thank you for your continuing support of UK NEQAS.

A handwritten signature in grey ink, appearing to read 'L. Whitley', is positioned above the printed name of the UK NEQAS President.

UK NEQAS President

Contents

Cellular Pathology	Page 5 Cellular Pathology Technique Head & Neck Pathology Neuropathology Immunocytochemistry & In-Situ Hybridisation
Clinical Chemistry	Page 6 - 7 Birmingham Quality Cardiac Markers Trace Elements Guildford Peptide Hormones Edinburgh Peptide Hormones
Haematology	Page 8 - 10 Blood Coagulation Blood Transfusion Laboratory Practice (BTLP) Haematology Vitamin K Leucocyte Immunophenotyping
Immunology	Page 11 - 12 Immunology, Immunochemistry & Allergy Histocompatibility and Immunogenetics
Medical Microbiology	Page 13 Microbiology Parasitology
Genomics & Reproductive Science	Page 14 - 17 Reproductive Science Genomics
Covid-19 Programmes	Page 18
Point of Care Testing	Page 19
A-Z Index	Page 20 - 26
Participating Countries	Page 27
UK NEQAS Contacts	Page 28

Cellular Pathology

Cellular Pathology Technique
Tel: +44 (0) 191 816 1030
Email: cpt@ukneqas.org.uk
Legal Entity: LabXCell LTD
Services Available
Tissue Diagnostics
Specialist Techniques
Bone Marrow Trephine Biopsy (BMT)
Diagnostic Cytopathology
Direct Immunofluorescence (DIF)
Mohs' Procedure
Muscle Histochemistry
Neuropathology
Renal Biopsy Pathology
Transmission Electron Microscopy (TEM)
Frozen Section (Companion Scheme to Specialist Techniques and Neuropathology)
Mega Block (Companion Scheme to Specialist Techniques and Neuropathology)
Digital Interpretative Diagnostic Cytopathology
Digital Diagnostic Ultrastructural Pathology*
Digital Pathology Imaging*

Head and Neck Pathology
Tel: +44 (0) 121 371 5723
Email: neckpath@ukneqas.org.uk
Legal Entity: British Society for Oral & Maxillofacial
Services Available
Head and Neck Pathology (Oral, ENT & Combined)

Neuropathology
Tel: +44 (0) 1865 234 904
Email: neuropath@ukneqas.org.uk
Legal Entity: Oxford University Hospitals NHS Foundation Trust
Services Available
Neuropathology Interpretative EQA Scheme

Immunocytochemistry & In-Situ Hybridisation	
Tel: +44 (0) 208 187 9174	
Email: info@ukneqasiccish.org	
Legal Entity: External Quality Assessment Services for Cancer Diagnostics CIC	
Services Available	
Immunocytochemistry	Alimentary Tract Pathology (GIST)
	Breast Pathology (HER2 IHC)
	Breast Pathology (Hormonal Receptors ER & PR)
	Breast Pathology (Hormonal Receptors ER only)
	Cytopathology
	Gastric HER2 IHC
	General Pathology
	Lymphoid Pathology
	Mismatch Repair (MMR) Proteins
	Neuropathology
	Non-Small Cell Lung Cancer (NSCLC) ALK IHC
	Non-Small Cell Lung Cancer (NSCLC) PD-L1 IHC*
	Non-Small Cell Lung Cancer (NSCLC) ROS1 IHC*
Triple Negative Breast Cancer (TNBC) PD-L1 IHC*	
In-Situ Hybridisation	Breast HER2 ISH (Interpretive and Technical)
	Non-Small Cell Lung Cancer (NSCLC) ALK ISH*
	Non-Small Cell Lung Cancer (NSCLC) ROS1 FISH*

Clinical Chemistry

Birmingham Quality

Tel: +44 (0) 121 414 7300

Email: birminghamquality@uhb.nhs.uk

Legal Entity: University Hospitals Birmingham
NHS Foundation Trust

Services Available

Antibiotic Assays
Antifungal Assays
Clinical Chemistry
Colorectal Cancer Screening
Erythropoietin
Faecal Haemoglobin
Faecal Markers
Faecal Pancreatic Elastase
Fluids
Fructosamine
GFR Estimations (Creatinine, Cystatin C & eGFR)
Glycated Haemoglobins
Haematinics
Holotranscobalamin
Immunosuppressants
Interpretative Comments in Clinical Chemistry
Intrinsic Factor Antibodies
Lipid Investigations
Newborn Screening
Paediatric Bilirubin
Quantitative Amino Acids
Serum Indices (HIL)
Specific Proteins
Steroid Hormones
Sweat Testing
Thyroglobulin
Thyroid Hormones
Toxicology (TOX) and Therapeutic Drug Monitoring (TDM)
Urinary Catecholamines & Metabolites
Urine Chemistries
Urine Dipsticks
Vitamin Assays (Carotene, Vitamin A & E)
Vitamin D

Cardiac Markers

Tel: +44 (0) 141 440 2888

Email: info@ukneqas-cm.org.uk

Legal Entity: NHS Greater Glasgow & Clyde

Services Available

Cardiac Markers Schemes (Laboratory)
Cardiac Markers Schemes (Point of Care)
B-Type Natriuretic Peptide (BNP)
Cardiac Troponin I
Cardiac Troponin T
CKMB
Myoglobin
NT-proBNP

Trace Elements

Tel: +44 (0) 1483 571 122 ext. 3611

Email: rsc-tr.Guildford-EQA@nhs.net

Legal Entity: Frimley Health NHS Foundation Trust

Services Available

Lead, Cadmium, Manganese, Arsenic, Magnesium, Mercury, Zinc, Selenium, Thallium, Chromium and Cobalt in Blood
Mercury, Cadmium, Copper, Iron, Zinc, Chromium, Cobalt, Arsenic, Lead, Manganese, Nickel, Thallium and Selenium in Urine
Zinc, Copper, Aluminium, Selenium, Chromium and Cobalt in Serum
Aluminium in Water/Dialysis Fluid (Educational)
Copper and Iron in Solid Matrices e.g. Liver (Educational)

Guildford Peptide Hormones

Tel: +44 (0) 1483 571 122 ext. 3611

Email: rsch.peptideeqa@nhs.net

Legal Entity: Frimley Health NHS Foundation Trust

Services Available

C-Peptide
Gastrin
Insulin
Insulin-like Growth Factor 1
Insulin-like Growth Factor Binding Protein-3

Clinical Chemistry

Edinburgh Peptide Hormones	
Tel: +44 (0) 131 242 6885	
Email: ukneqas@ed.ac.uk	
Legal Entity: NHS Lothian	
Services Available	
Maternal Serum Screening	1st Trimester (Down's syndrome and Trisomies T13 and T18)
	2nd Trimester (Down's syndrome)
	2nd Trimester (Neural tube defects)
	1st Trimester (Down's syndrome using dried blood spots)
Pre-eclampsia Markers*	Placental Growth Factor (PLGF)
	SFlt-1
	SFlt-1: PLGF ratio
Peptide I	FSH, LH, AMH, Prolactin and Growth Hormone
Peptide II	PTH, ACTH and Calcitonin
Tumour Markers	AFP, CEA and hCG
Pregnancy Testing	Urinary hCG (Qualitative and Quantitative)
Liver Fibrosis Markers*	Type III Procollagen Peptide (PIIINP)
	Hyaluronic acid
	Tissue inhibitor of metalloproteinase I (TIMP-I)
	Enhanced Liver Fibrosis (ELF) Score
	FIB-4 Score

Haematology

Blood Coagulation	
Tel: +44 (0) 114 267 3300	
Email: neqas@coageqa.org.uk	
Legal Entity: Sheffield Teaching Hospitals NHS Foundation Trust	
Services Available	
Screening tests	Activated Partial Thromboplastin Time (APTT)
	D-Dimer
	Fibrinogen Evaluation (Clauss method)
	Heparin Assay (HA) - anti-Xa
	Heparin Dosage Assessment (HDA) by APTT
	Prothrombin Time (PT)/INR (Venous/Capillary methods)
	Prothrombin Time for Diagnosis (PT/Diagnostic) (PTD)
	Thrombin Time (TT)
	Factor II, V, VII VIII, IX, X, XI, XII Assays
Assays	Direct Oral Anticoagulant (DOAC) Assay*
	Von Willebrand Factor Antigen: Assay
	VWF:RCo (activity) Assay
	VWF:CB (collagen-binding) Assay
	Antithrombin Antigen and Activity Assays
	Protein C Antigen and Activity Assay
	Protein S Total and Free Antigen Assay

Blood Coagulation Continued	
Assays	Protein S Activity Assay
	Activated Protein C Resistance Assay
	Plasminogen Assay
Other programmes	DOAC assays
	FXIII assays
	Homocysteine assays
	Quantitative Factor VIII Inhibitor
	ADAMTS13 assays
	Lupus anticoagulant screening/assay
	FVIII treatment monitoring
	FIX treatment monitoring
	Emicizumab assays
	HIT screening/assays
	Molecular Genetics of Thrombophilia Testing (Factor V Leiden)
Genetics of Heritable Bleeding and Thrombotic disorders	
POCT	Activated Clotting Time (ACT)
	POCT D-dimer
	CoaguChek XS, CoaguChek XS Plus, CoaguChek XS Pro & Pro II (PT/INR)
	Thromboelastometry and Thromboelastography

Haematology

Blood Transfusion Laboratory Practice (BTLP)	
Tel: +44 (0) 1923 217 933	
Email: btlp@ukneqas.org.uk	
Legal Entity: West Hertfordshire Hospitals NHS Trust	
Services Available	
Pre-Transfusion Testing (PTT)	ABO & D Grouping
	Antibody Screening
	Antibody Identification
	Crossmatching
	Rh and K Phenotyping
Fetomaternal Haemorrhage (FMH)	FMH Screening
	FMH Quantification
ABO Titration (ABOT)	ABO Titration
	A ₁ typing
Direct Antiglobulin Testing (DAT)	Detection of cells coated with IgG
	Detection of cells coated with C3d
Point of Care D typing (POCTD)	RhD typing
Pilot schemes	Red Cell Genotyping (RCG)*
	Antenatal Antibody Titration (ANT)*
	Extended Red Cell Phenotyping (ERP)*
Other services (supplementary to EQA)	Training, Assessment and Competency Tool (TACT)

Vitamin K	
Tel: +44 (0) 207 188 6815	
Email: keqas@ukneqas.org.uk	
Legal Entity: Viapath Analytics	
Services Available	
Vitamin K1 at endogenous concentrations in human serum	
MK-4 at endogenous concentrations in human serum	
MK-7 at endogenous concentrations in human serum	
Vitamin K1, 2, 3-epoxide at endogenous concentrations in human serum	
PIVKA-II (undercarboxylated prothrombin) at endogenous concentrations in human serum	

Haematology	
Tel: +44 (0) 1923 217 878	
Email: haem@ukneqas.org.uk	
Legal Entity: West Hertfordshire Hospitals NHS Trust	
Services Available	
Automated Counting & Related	Automated Differential Leucocyte Count
	ESR
	Full Blood Count (FBC)
	Haemoglobin only
	Plasma Viscosity
	Infectious Mononucleosis*
Haemoglobinopathy	Reticulocyte Count
	Abnormal Haemoglobins
	DNA Diagnostics for Haemoglobinopathies
	Liquid Newborn Haemoglobinopathy Screening
	Newborn Sickle Screening
	Sickle Screening only
Morphology Related	Blood Films for Morphology
	Blood Parasite Screening and Identification (Haematology)
	Cytochemistry: Haemosiderin Staining
	Digital Blood Film Morphology for CPD
	Rapid Diagnostic Tests for Malaria (Haematology)
	Manual WBC Differential Count
Red Cell Enzyme	G6PD Screen and Assay

*Pilot/Non Accredited

For accreditation status please refer to www.ukas.com

Haematology

Leucocyte Immunophenotyping	
Tel: +44 (0) 114 267 3600	
Email: admin@uknegasli.co.uk	
Legal Entity: Sheffield Teaching Hospitals NHS Foundation Trust	
Services Available	
Flow Cytometry	CD34+ Stem Cell Enumeration
	Immune Monitoring
	Leukaemia Immunophenotyping (Part 1)
	Leukaemia Diagnostic Interpretation (Part 2)
	Low Level Leucocyte Enumeration
	Minimal Residual Disease for ALL by Flow Cytometry
	Minimal Residual Disease for AML by Flow Cytometry*
	Minimal Residual Disease for CLL by Flow Cytometry*
	Minimal Residual Disease for Plasma Cell Myeloma by Flow Cytometry*
	Haematological Malignancy Bone Marrow Aspirate Assessment*
	Cerebrospinal Fluid (CSF) Immunophenotyping*
Paroxysmal Nocturnal Haemoglobinuria	
Molecular	BCR-ABL1 and AML Translocation Identification
	BCR-ABL1 Kinase Domain Variant (Mutation) Status
	BCR-ABL1 Major Quantification

Leucocyte Immunophenotyping Continued	
Molecular	BCR-ABL1 Minor Quantification*
	BRAF p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia
	FLT3 Mutation Status
	IgH/TCR Clonality Status
	JAK2 p.Val617Phe (V617F) Mutation Status
	KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease
	NPM1 Mutation Status
	Paediatric Acute Leukaemia Translocations
	Post-Stem Cell Transplant Chimerism Monitoring
	Acute Myeloid Leukaemia and Myelodysplastic Syndrome Gene Panels*
	Chronic Lymphocytic Leukaemia Gene Panels*
	Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia*
	Myeloproliferative Neoplasm Gene Panels*

*Pilot/Non Accredited

For accreditation status please refer to www.ukas.com

Immunology

Immunology, Immunochemistry & Allergy	
Tel: +44 (0) 114 271 5715	
Email: immunology@ukneqas.org.uk	
Legal Entity: Sheffield Teaching Hospitals NHS Foundation Trust	
Services Available	
Allergy and Immunodeficiency	Allergen Component Testing
	Allergen Specific IgE
	Antibody to Fungal & Related Antigens
	IgG Subclasses
	Specific Microbial Antibodies
	Total IgE
	Tryptase
Autoimmunity	Acetylcholine Receptor Antibodies
	ANCA/GBM Antibodies
	Antibodies to Nuclear and Related Antigens
	Bullous Dermatitis Antibodies
	Coeliac Disease Antibodies
	Diabetic Markers
	Ganglioside Antibodies
	General Autoimmune Serology
	Interferon Gamma Release Assays (Mycobacterium tuberculosis) IGRA TB
	Myelin Associated Glycoprotein IgM Antibodies (MAG)
	Myositis Associated Antibodies
	Paraneoplastic Antibodies

IIA continued		
Autoimmunity	Phospholipase A2 Receptor Antibodies (PLA2R)	
	Phospholipid Antibodies	
	SARS-CoV-2 Antibody Detection	
Immunochemistry	Alkaline Phosphatase (ALP) Isoenzymes	
	Alpha 1 Antitrypsin and Phenotype Identification	
	C-Reactive Protein (CRP)	
	C1 Esterase Inhibitor and Functional Complement Assays	
	CSF Haem Pigments	
	CSF IgG Oligoclonal Bands	
	CSF Proteins and Biochemistry	
	CSF β 2 Transferrin/Beta Trace Protein	
	Interleukin-6 (IL-6)*	
	Point of Care CRP	
	Procalcitonin	
	Ultrasensitive C-Reactive Protein	
	β 2 Microglobulin	
	Oncology	Cryoproteins (image based)
		Monoclonal Protein Identification
Prostate Specific Antigen (PSA)		
Ultrasensitive PSA		
Tumour Markers (CA Series)		

Immunology

Histocompatibility and Immunogenetics

Tel: +44 (0) 1443 622 185

Email: handi@ukneqas.org.uk

Legal Entity: Velindre University NHS Trust

Services Available

Crossmatching by Flow Cytometry

Cytotoxic Crossmatching

DNA HLA Typing at 1st Field Resolution

DNA HLA Typing to 2nd or 3rd Field Resolution

Educational Cross Match

Educational Interpretive Clinical Scenarios

Educational Scheme

HFE Typing

HLA Antibody Detection

HLA Antibody Specificity Analysis

HLA Genotyping for Coeliac and other HLA associated diseases

HLA Phenotyping

HLA-B*57:01 Typing for Drug Hypersensitivity

HLA-B27 Testing

HPA Antibody Detection/Specification

HPA Genotyping

Interpretative: HFE Genotype and Hereditary Haemochromatosis

Interpretive HLA Genotype

KIR Genotyping

Medical Microbiology

Microbiology	
Tel: +44 (0) 208 905 9890	
Email: organiser@ukneqasmicro.org.uk	
Legal Entity: Public Health England	
Services Available	
Bacteriology	AAFB Microscopy
	Antimicrobial Susceptibility
	Clostridioides Difficile (prev. Clostridium Difficile)
	Community Medicine
	Faecal Pathogens
	General Bacteriology
	Genital pathogens
	MRSA Screening
	Mycobacteria Culture
	Syphilis Serology
	Urinary Antigens
	Molecular
CMV DNA Quantification	
EBV DNA Quantification	
HBV DNA Quantification	
Hepatitis C RNA Detection	
HIV 1 RNA Quantification	
Molecular Detection Mycobacteria	
Molecular detection of HEV RNA	
Molecular Detection of HPV	
Molecular Detection of Respiratory Viruses	
Molecular Detection of SARS-CoV-2	
Molecular Detection of Viruses in CSF	
Viral Gastroenteritis (also suitable for antigen testing)	

Microbiology continued	
Mycology	Antifungal Susceptibility
	Cryptococcal antigen detection
	Fungal Biomarkers
	Mycology
Virology	Anti-HBs detection
	Blood Borne Viruses
	Blood Donor Screen
	Diagnostic Serology: hepatitis screen
	Hepatitis B Serology
	Hepatitis C Serology
	Hepatitis E Serology
	HIV Point of Care
	HIV Serology
	Immunity Screen
	Measles and Mumps IgG Serology
	Parvovirus B19 and Rubella Serology
Respiratory Rapid: RSV	
Rubella IgG Serology	
Virus identification	

Parasitology	
Tel: +44 (0) 203 908 1371	
Email: parasite@ukneqas.org.uk	
Legal Entity: Public Health England	
Services Available	
Blood Parasitology	
Faecal Parasitology	
Malaria Rapid	
Molecular Diagnosis of Malaria	
Parasite Serology	
Toxoplasma Serology	
Molecular detection of Faecal Parasites	
Teaching for Blood and Faecal Parasites	

Genomics and Reproductive Science

Reproductive Science	
Tel: +44 (0) 161 276 6437	
Email: repscience@ukneqas.org.uk	
Legal Entity: Manchester University NHS Foundation Trust	
Services Available	
Andrology: Semen Analysis (Sperm Motility, Concentration & Morphology)	
Embryology: Embryo Morphology, Time Lapse Annotation	

Genomics (GenQA)	
Tel:	
Oxford Office: +44 (0) 1865 857 644	
Edinburgh Office: +44 (0) 131 242 6898	
Email: info@genqa.org	
Legal Entity: Oxford University Hospitals NHS Foundation Trust/ NHS Lothian	

Services Available	
Clinical Genetics	Cardiovascular Disorders
	Dysmorphology
	Monogenic Disorders
	Oncogenetics
	Genetic Counselling*
Constitutional - Postnatal	Chromosome Breakage syndromes
	Disorders of Sexual Development*
	Induced Pluripotent stem (IPS) cells
	Infertility*
	Microdeletion syndromes*
	Postnatal constitutional Copy Number Variant (CNV) detection
	Recurrent miscarriage karyotyping
	Severe Developmental Delay*
Sex chromosome disorders karyotyping	

Genomics continued	
Haematological Neoplasms	Acquired array (CLL and MDS)
	Acute Lymphoblastic Leukaemia (ALL)
	Chronic Lymphocytic Leukaemia (CLL)
	Chronic Lymphocytic Leukaemia (CLL) IGHV mutation status*
	Chronic Lymphocytic Leukaemia (CLL) TP53 mutation analysis*
	Haematological Technical FISH
	Haematological Translocations*
	Lymphoma
	Lymphoma Technical NGS*
	Myeloid Disorders
Myeloma	
Individual Competency Assessment	Tissue-i
	BRCA and HRR variant classification
	COVID-19 Care Home Swabbing
	COVID-19 Laboratory Testing
	COVID-19 Direct LAMP assay
	COVID-19 LamPORE assay
Molecular Genetic Disorders	COVID-19 High throughput Direct RT-LAMP assay
	Aminoglycoside-Induced deafness*
	Ataxia & Hereditary Spastic Paraplegia (HSP)
	Cardiac Disorders
	Charcot Marie Tooth disease (CMT) and related sensory and motor neuropathies

Genomics and Reproductive Science

Genomics continued	
Molecular Genetic Disorders	Cystic Fibrosis (CF) and CFTR-related disorders
	Epilepsy Disorders
	Eye Disorders
	Familial Colorectal Cancer and Polyposis
	Familial Hypercholesterolaemia (FH)
	Familial endocrine tumour predisposition disorders
	Fragile X syndrome and FMR1-related disorders
	Gastrohepatology disorders*
	Hereditary Breast and Ovarian Cancer (HBOC) disorders
	Huntington disease (HD)
	Hypotonic Infant
	Imprinting disorders
	Inborn Errors of Metabolism (IEM)
	Linkage analysis
	Mitochondrial and POLG-related disorders
	Muscular Dystrophies
	Neurodegenerative Disorders
	Neurofibromatosis type 1 and Rasopathies
	Osteogenesis Imperfecta (OI)
	Prediction of 5-Fluorouracil Toxicity (DPYD)*
Primary Immunodeficiency disorders (PID)	

Genomics continued	
Molecular Genetic Disorders	Renal Disorders
	Respiratory disorders
	Skeletal Dysplasias
	X-Inactivation
Molecular Newborn Screening	Cystic Fibrosis (CF) Molecular Newborn screening (bloodspots)
	MCADD Molecular Newborn Screening (bloodspots)
	SCID Molecular Newborn Screening (bloodspots)*
Molecular Pathology	BRCA testing for ovarian cancer - somatic
	BRCA testing for ovarian, breast, prostate and pancreatic cancer - germline
	Breast cancer (PIK3CA testing)*
	Breast cancer - Tumour Expression profiling*
	Central Nervous System (CNS) Tumours
	Circulating free (cf) DNA testing in lung cancer
	Gastrointestinal stromal tumours (GIST)
	Microsatellite instability testing (MSI)
	Molecular Tissue Identification
	NTRK fusions*
	Neuroblastoma*

Genomics and Reproductive Science

Genomics continued	
Molecular Pathology	Prostate cancer (HRR testing)*
	Renal Tumours*
	Sarcoma
	Thyroid Cancer*
	Colorectal cancer - Extended MMR
	Colorectal cancer - MMR
	Colorectal cancer - core
	Lung cancer - EGFR only
	Lung cancer - comprehensive
	Lung cancer - core
	Lung cancer - fusions
Melanoma	
Preimplantation Genetic Testing (PGT)	Preimplantation genetic testing (PGT) for aneuploidy
	Preimplantation genetic testing (PGT) for chromosomal rearrangements
	Preimplantation genetic testing (PGT) of Blastomere (FISH)
	Preimplantation genetic testing (PGT) of Polar Body
	Preimplantation Genetic Testing (PGT) for monogenic disorders
Prenatal Testing	Maternal cell contamination (MCC) & sexing
	Non-invasive prenatal testing (NIPT) for aneuploidies

Genomics continued	
Prenatal Testing	Non-invasive prenatal testing (NIPT) for common microdeletions*
	Non-invasive prenatal testing (NIPT) for sexing
	Pregnancy loss (G-banding)
	Pregnancy loss (Molecular methods)
	Prenatal constitutional Copy Number Variant (CNV) detection
	Prenatal karyotyping
	Rapid Prenatal Testing for common aneuploidies
Sample Handling	DNA Quantification*
	DNA extraction from formalin-fixed paraffin-embedded (FFPE) tissue
	DNA extraction from fresh frozen (FF) tissue*
	DNA extraction from saliva*
	DNA extraction from venous blood
Technical (Next Generation Sequencing)	Next Generation Sequencing (NGS) germline
	Next Generation Sequencing (NGS) somatic WES/WGS*
	Next Generation Sequencing (NGS) somatic panel

Genomics and Reproductive Science

Genomics continued	
Variant Classification	Exome Sequencing Data Interpretation*
	ISCN (International System for Human Cytogenomic Nomenclature) (Classification Only)*
	Pathogenicity of germline postnatal copy number variants (CNV) (Classification Only)*
	Pathogenicity of germline sequence variants (Classification & Interpretation)
	Pathogenicity of germline sequence variants (Classification only)
	Pathogenicity of prenatal copy number variants (Classification only)*
	Pathogenicity of somatic sequence variants (Classification only)*
	Variant Validation

Covid-19 Programmes

Purpose	Services Available	UK NEQAS Provider
Diagnostic Programmes	Molecular Detection of Respiratory Viruses	UK NEQAS Microbiology
	Molecular Detection of SARS-CoV-2	UK NEQAS Microbiology
	SARS-CoV-2 Antibody Detection	UK NEQAS Immunology, Immunochemistry & Allergy
	SARS-CoV-2 Antigen*	UK NEQAS Microbiology
Treatment & Monitoring Programmes	Activated Partial Thromboplastin Time (APTT)	UK NEQAS Blood Coagulation
	B-Type Natriuretic Peptide (BNP)	UK NEQAS Cardiac Markers
	C-Reactive Protein	UK NEQAS Immunology, Immunochemistry & Allergy
	Point of Care CRP*	UK NEQAS Immunology, Immunochemistry & Allergy
	D-Dimer Assay (within Screening Tests)	UK NEQAS Blood Coagulation
	Ferritin (within Haematinics EQA Programme)	UK NEQAS Birmingham Quality
	Full Blood Count (FBC)	UK NEQAS Haematology
	Heparin Induced Thrombophilia (HIT) Screening (within Screening Tests)	UK NEQAS Blood Coagulation
	Interleukin-6 (IL-6)*	UK NEQAS Immunology, Immunochemistry & Allergy
	Monitoring Anticoagulation with Low Molecular Weight Heparin (UFH) (within Screening Tests)	UK NEQAS Blood Coagulation
	NT-pro BNP	UK NEQAS Cardiac Markers
	Plasma Viscosity	UK NEQAS Haematology
	Procalcitonin	UK NEQAS Immunology, Immunochemistry & Allergy
	Prothrombin Time for Diagnosis (PT/Diagnostic) (PTD)	UK NEQAS Blood Coagulation
	Routine Biochemistry	UK NEQAS Birmingham Quality
	Cardiac Troponin I	UK NEQAS Cardiac Markers
	Cardiac Troponin T	UK NEQAS Cardiac Markers
Educational Modules	Covid-19 Care Home Swabbing	UK NEQAS Genomics
	Covid-19 Laboratory Testing	UK NEQAS Genomics
	Covid-19 LAMP Assay	UK NEQAS Genomics
	Covid-19 LamPORE Assay	UK NEQAS Genomics
	Covid-19 High Throughput Direct RT-LAMP Assay	UK NEQAS Genomics

Point of Care Testing

Services Available	UK NEQAS Provider
Activated Clotting Time (ACT)	UK NEQAS Blood Coagulation
B-Type Natriuretic Peptide (BNP)	UK NEQAS Cardiac Markers
Cardiac Troponin I	UK NEQAS Cardiac Markers
Cardiac Troponin T	UK NEQAS Cardiac Markers
CKMB	UK NEQAS Cardiac Markers
Clinical Chemistry	UK NEQAS Birmingham Quality
CoaguChek XS, CoaguChek XS Plus, CoaguChek XS Pro & Pro II (PT/INR)	UK NEQAS Blood Coagulation
C-Reactive Protein (CRP)*	UK NEQAS Immunology, Immunochemistry & Allergy
D-Dimer	UK NEQAS Blood Coagulation
D-Typing	UK NEQAS BTLP
Fungal Biomarkers	UK NEQAS Microbiology
Glycated Haemoglobins	UK NEQAS Birmingham Quality
Haemoglobin only	UK NEQAS Haematology
HIV	UK NEQAS Microbiology
Malaria Rapid	UK NEQAS Parasitology
Molecular Detection of Respiratory Viruses	UK NEQAS Microbiology
Myoglobin	UK NEQAS Cardiac Markers
NT-pro BNP	UK NEQAS Cardiac Markers
Pregnancy Testing	UK NEQAS Edinburgh
Respiratory Rapid: RSV	UK NEQAS Microbiology
Thromboelastometry and Thromboelastography	UK NEQAS Blood Coagulation
Urinary Antigens	UK NEQAS Microbiology
Urine Dipsticks	UK NEQAS Birmingham Quality
Viral Gastroenteritis (also suitable for antigen testing)	UK NEQAS Microbiology

Index

#			
1st Trimester (Down's syndrome and Trisomies T13 and T18)	7	Antibody to Fungal & Related Antigens	11
1st Trimester (Down's syndrome using dried blood spots)	7	Antifungal Assays	6
2nd Trimester (Down's syndrome)	7	Antifungal Susceptibility	13
2nd Trimester (Neural tube defects)	7	Anti-HBs detection	13
β 2 Microglobulin	11	Antimicrobial Susceptibility	13
		Antithrombin Antigen and Activity Assays	8
A		Assays (Blood Coagulation)	8
A ₁ typing	9	Ataxia & Hereditary Spastic Paraplegia (HSP)	14
AAFB Microscopy	13	Autoimmunity	11
Abnormal Haemoglobins	9	Automated Counting & Related (Haematology)	9
ABO & D Grouping	9	Automated Differential Leucocyte Count	9
ABO Titration	9		
ABO Titration (ABOT)	9	B	
Acetylcholine Receptor Antibodies	11	Bacteriology	13
Acquired array (CLL and MDS)	14	BCR-ABL1 and AML Translocation Identification	10
Activated Clotting Time (ACT)	8, 19	BCR-ABL1 Kinase Domain Variant (Mutation) Status	10
Activated Partial Thromboplastin Time (APTT)	8, 18	BCR-ABL1 Major Quantification	10
Activated Protein C Resistance Assay	8	BCR-ABL1 Minor Quantification*	10
Acute Lymphoblastic Leukaemia (ALL)	14	Blood Borne Viruses	13
Acute Myeloid Leukaemia and Myelodysplastic Syndrome Gene Panels*	10	Blood Donor Screen	13
ADAMTS13 assays	8	Blood Films for Morphology	9
AFP, CEA and hCG	7	Blood Parasite Screening and Identification (Haematology)	9
Alimentary Tract Pathology (GIST)	5	Blood Parasitology	13
Alkaline Phosphatase (ALP) Isoenzymes	11	Bone Marrow Trephine Biopsy (BMT)	5
Allergen Component Testing	11	BRAF p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia	10
Allergen Specific IgE	11	BRCA and HRR variant classification	14
Allergy and Immunodeficiency	11	BRCA testing for ovarian cancer - somatic	15
Alpha 1 Antitrypsin and Phenotype Identification	11	BRCA testing for ovarian, breast, prostate and pancreatic cancer - germline	15
Aluminium in Water/Dialysis Fluid (Educational)	6	Breast cancer - Tumour Expression profiling*	15
Aminoglycoside-Induced deafness*	14	Breast cancer (PIK3CA testing)*	15
ANCA/GBM Antibodies	11	Breast HER2 ISH (Interpretive and Technical)	5
Andrology: Semen Analysis (Sperm Motility, Concentration & Morphology)	14	Breast Pathology (HER2 IHC)	5
Antenatal Antibody Titration (ANT)	9	Breast Pathology (Hormonal Receptors ER & PR)	5
Antibiotic Assays	6	Breast Pathology (Hormonal Receptors ER only)	5
Antibodies to Nuclear and Related Antigens	11	B-Type Natriuretic Peptide (BNP)	6, 18, 19
Antibody Identification	9	Bullous Dermatositis Antibodies	11
Antibody Screening	9		

Index

C	
C. trachomatis and N. gonorrhoeae	13
C1 Esterase Inhibitor and Functional Complement Assays	11
Cardiac Disorders	14
Cardiac Markers Schemes (Point of Care)	6
Cardiac Markers Schemes (Laboratory)	6
Cardiac Troponin I	6, 18, 19
Cardiac Troponin T	6, 18, 19
Cardiovascular Disorders	14
CD34+ Stem Cell Enumeration	10
Central Nervous System (CNS) Tumours	15
Cerebrospinal Fluid (CSF) Immunophenotyping*	10
Charcot Marie Tooth disease (CMT) and related sensory and motor neuropathies	14
Chromosome Breakage syndromes	14
Chronic Lymphocytic Leukaemia (CLL)	14
Chronic Lymphocytic Leukaemia (CLL) IGHV mutation status*	14
Chronic Lymphocytic Leukaemia (CLL) TP53 mutation analysis*	14
Chronic Lymphocytic Leukaemia Gene Panels*	10
Circulating free (cf) DNA testing in lung cancer	15
CKMB	6, 19
Clinical Chemistry	6, 19
Clinical Genetics	14
Clostridioides Difficile (prev. Clostridium Difficile)	13
CMV DNA Quantification	13
CoaguChek XS, CoaguChek XS Plus, CoaguChek XS Pro & Pro II (PT/INR)	8, 19
Coeliac Disease Antibodies	11
Colorectal cancer - core	16
Colorectal cancer - Extended MMR	16
Colorectal cancer - MMR	16
Colorectal Cancer Screening	6
Community Medicine	13
Constitutional Postnatal	14
Copper and Iron in Solid Matrices e.g. Liver (Educational)	6
COVID-19 Care Home Swabbing	14, 18
COVID-19 Direct LAMP assay	14, 18
COVID-19 High throughput Direct RT-LAMP assay	14, 18
COVID-19 Laboratory Testing	14, 18
COVID-19 LamPORE assay	14, 18
C-Peptide	6
C-Reactive Protein (CRP)	11, 18, 19
Crossmatching	9
Crossmatching by Flow Cytometry	12
Cryoproteins (image based)	11
Cryptococcal antigen detection	13
CSF Haem Pigments	11
CSF IgG Oligoclonal Bands	11
CSF Proteins and Biochemistry	11
CSF β 2 Transferrin/Beta Trace Protein	11
Cystic Fibrosis (CF) and CFTR-related disorders	15
Cystic Fibrosis (CF) Molecular Newborn screening (bloodspots)	15
Cytochemistry: Haemosiderin staining	9
Cytopathology	5
Cytotoxic Crossmatching	12
D	
D-Dimer	8, 18, 19
Detection of cells coated with C3d	9
Detection of cells coated with IgG	9
Diabetic Markers	11
Diagnostic Cytopathology	5
Diagnostic Programmes (Covid-19)	18
Diagnostic Serology: hepatitis screen	13
Digital Blood Film Morphology for CPD	9
Digital Diagnostic Ultrastructural Pathology*	5
Digital Interpretative Diagnostic Cytopathology	5
Digital Pathology Imaging*	5
Direct Antiglobulin Testing (DAT)	9
Direct Immunofluorescence (DIF)	5
Direct Oral Anticoagulant (DOAC) Assay*	8
Disorders of Sexual Development*	14
DNA Diagnostics for Haemoglobinopathies	9
DNA extraction from formalin-fixed paraffin-embedded (FFPE) tissue	16
DNA extraction from fresh frozen (FF) tissue*	16
DNA extraction from saliva*	16
DNA extraction from venous blood	16
DNA HLA Typing at 1st Field Resolution	12
DNA HLA Typing to 2nd or 3rd Field Resolution	12
DNA Quantification*	16
DOAC assays	8
Dysmorphology	14

Index

E			
EBV DNA Quantification	13	Full Blood Count (FBC)	9, 18
Educational Cross Match (Histocompatibility & Immunogenetics)	12	Fungal Biomarkers	13, 19
Educational Interpretive Clinical Scenarios (Histocompatibility & Immunogenetics)	12	FVIII treatment monitoring	8
Educational Scheme (Histocompatibility & Immunogenetics)	12	FXIII assays	8
Embryology: Embryo Morphology, Time Lapse Annotation	14	G	
Emicizumab assays	8	G6PD Screen and Assay	9
Enhanced Liver Fibrosis (ELF) Score	7	Ganglioside Antibodies	11
Erythropoietin	6	Gastric HER2 IHC	5
ESR	9	Gastrin	6
Exome Sequencing Data Interpretation*	17	Gastrohepatology disorders*	15
Extended Red Cell Phenotyping (ERP)	9	Gastrointestinal stromal tumours (GIST)	15
Epilepsy Disorders	15	General Autoimmune Serology	11
Eye Disorders	15	General Bacteriology	13
Educational Modules (Covid-19)	18	General Pathology	5
F		Genetic Counselling*	14
Factor II, V, VII VIII, IX, X, XI, XII Assays	8	Genetics of Heritable Bleeding and Thrombotic disorders	8
Faecal Haemoglobin	6	Genital pathogens	13
Faecal Markers	6	GFR Estimations (Creatinine, Cystatin C & eGFR)	6
Faecal Pancreatic Elastase	6	Glycated Haemoglobins	6, 19
Faecal Parasitology	13	H	
Faecal Pathogens	13	Haematinics	6, 18
Familial Colorectal Cancer and Polyposis	15	Haematological Malignancy Bone Marrow Aspirate Assessment*	10
Familial endocrine tumour predisposition disorders	15	Haematological Neoplasms	14
Familial Hypercholesterolaemia (FH)	15	Haematological Technical FISH	14
Ferritin	18	Haematological Translocations*	14
Fetomaternal Haemorrhage (FMH)	9	Haemoglobin only	9, 19
FIB-4 Score	7	Haemoglobinopathy	9
Fibrinogen Evaluation (Clauss method)	8	HBV DNA Quantification	13
FIX treatment monitoring	8	Head and Neck Pathology (Oral, ENT & Combined)	5
Flow Cytometry	10	Heparin Assay (HA) - anti-Xa	8
FLT3 Mutation Status	10	Heparin Dosage Assessment (HDA) by APTT	8
Fluids	6	Heparin Induced Thrombophilia (HIT) Screening	18
FMH Quantification	9	Hepatitis B Serology	13
FMH Screening	9	Hepatitis C RNA Detection	13
Fragile X syndrome and FMR1-related disorders	15	Hepatitis C Serology	13
Frozen Section (Companion Scheme to Specialist Techniques and Neuropathology)	5	Hepatitis E Serology	13
Fructosamine	6	Hereditary Breast and Ovarian Cancer (HBOC) disorders	15
FSH, LH, AMH, Prolactin and Growth Hormone	7	HFE Typing	12
		HIT screening/assays	8
		HIV 1 RNA Quantification	13
		HIV Point of Care	13, 19

Index

H continued

HIV Serology	13
HLA Antibody Detection	12
HLA Antibody Specificity Analysis	12
HLA Genotyping for Coeliac and other HLA associated diseases	12
HLA Phenotyping	12
HLA-B*57:01 Typing for Drug Hypersensitivity	12
HLA-B27 Testing	12
Holo-transcobalamin	6
Homocysteine assays	8
HPA Antibody Detection/Specification	12
HPA Genotyping	12
Huntington disease (HD)	15
Hyaluronic acid	7
Hypotonic Infant	15

I

IgG Subclasses	11
IgH/TCR Clonality Status	10
Immune Monitoring	10
Immunity Screen	13
Immunochemistry	11
Immunocytochemistry	5
Immunosuppressants	6
Individual Competency Assessment (Genomics)	14
Induced Pluripotent stem (IPS) cells	14
Infectious Mononucleosis*	9
Infertility*	14
In-Situ Hybridisation	5
Insulin	6
Insulin-like Growth Factor 1	6
Insulin-like Growth Factor Binding Protein-3	6
Interferon Gamma Release Assays (Mycobacterium tuberculosis) IGRA TB	11
Interleukin-6 (IL-6)*	11, 18
Interpretative Comments in Clinical Chemistry	6
Interpretative: HFE Genotype and Hereditary Haemochromatosis	12
Interpretive HLA Genotype	12
Intrinsic Factor Antibodies	6
ISCN (International System for Human Cytogenomic Nomenclature) (Classification Only)*	17
Imprinting disorders	15
Inborn Errors of Metabolism (IEM)	15

J

JAK2 p.Val617Phe (V617F) Mutation Status	10
--	----

K

KIR Genotyping	12
KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease	10

L

Lead, Cadmium, Manganese, Arsenic, Magnesium, Mercury, Zinc, Selenium, Thallium, Chromium and Cobalt in Blood	6
Leukaemia Diagnostic Interpretation (Part 2)	10
Leukaemia Immunophenotyping (Part 1)	10
Linkage analysis	15
Lipid Investigations	6
Liquid Newborn Haemoglobinopathy Screening	9
Liver Fibrosis Markers*	7
Low Level Leucocyte Enumeration	10
Lung cancer - comprehensive	16
Lung cancer - core	16
Lung cancer - EGFR only	16
Lung cancer - fusions	16
Lupus anticoagulant screening/assay	8
Lymphoid Pathology	5
Lymphoma	14
Lymphoma Technical NGS*	14
Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinaemia*	10

M

Malaria Rapid	13, 19
Malaria Rapid Diagnostic Test (Haematology)	9
Manual WBC Differential Count	9
Maternal cell contamination (MCC) & sexing	16
Maternal Serum Screening	7
MCADD Molecular Newborn Screening (bloodspots)	15
Measles and Mumps IgG Serology	13
Mega Block (Companion Scheme to Specialist Techniques and Neuropathology)	5
Melanoma	16
Mercury, Cadmium, Copper, Iron, Zinc, Chromium, Cobalt, Arsenic, Lead, Manganese, Nickel, Thallium and Selenium in Urine	6

Index

M continued

Microdeletion syndromes*	14
Microsatellite instability testing (MSI)	15
Minimal Residual Disease for ALL by Flow Cytometry	10
Minimal Residual Disease for AML by Flow Cytometry*	10
Minimal Residual Disease for CLL by Flow Cytometry*	10
Minimal Residual Disease for Plasma Cell Myeloma by Flow Cytometry*	10
Mismatch Repair (MMR) Proteins	5
Mitochondrial and POLG-related disorders	15
Mk-4 at endogenous concentrations in human serum	9
MK-7 at endogenous concentrations in human serum	9
Mohs' Procedure	5
Molecular (Leucocyte Immunophenotyping)	10
Molecular (Microbiology)	13
Molecular Detection Mycobacteria	13
Molecular detection of Faecal Parasites	13
Molecular detection of HEV RNA	13
Molecular Detection of HPV	13
Molecular Detection of Respiratory Viruses	13, 18, 19
Molecular Detection of SARS-CoV-2	13, 18
Molecular Detection of Viruses in CSF	13
Molecular Diagnosis of Malaria	13
Molecular Genetic Disorders	14, 15
Molecular Genetic Disorders	15
Molecular Genetics of Thrombophilia Testing (Factor V Leiden)	8
Molecular Newborn Screening	15
Molecular Pathology	15, 16
Molecular Tissue Identification	15
Monitoring Anticoagulation with Low Molecular Weight Heparin (UFH)	18
Monoclonal Protein Identification	11
Monogenic Disorders	14
Morphology Related	9
MRSA Screening	13
Muscle Histochemistry	5
Muscular Dystrophies	15
Mycobacteria Culture	13
Mycology	13
Myelin Associated Glycoprotein IgM Antibodies (MAG)	11
Myeloid Disorders	14
Myeloma	14

Myeloproliferative Neoplasm Gene Panels*	10
Myoglobin	6, 19
Myositis Associated Antibodies	11

N

Neuroblastoma*	15
Neurodegenerative Disorders	15
Neurofibromatosis type 1 and Rasopathies	15
Neuropathology (Cellular Pathology Technique)	5
Neuropathology (Immunocytochemistry)	5
Neuropathology Interpretative EQA Scheme	5
Newborn Screening	6
Newborn Sickle Screening	9
Next Generation Sequencing (NGS) germline	16
Next Generation Sequencing (NGS) somatic panel	16
Next Generation Sequencing (NGS) somatic WES/WGS*	16
Non-invasive prenatal testing (NIPT) for aneuploidies	16
Non-invasive prenatal testing (NIPT) for common microdeletions*	16
Non-invasive prenatal testing (NIPT) for sexing	16
Non-Small Cell Lung Cancer (NSCLC) ALK IHC	5
Non-Small Cell Lung Cancer (NSCLC) ALK ISH*	5
Non-Small Cell Lung Cancer (NSCLC) PD-L1 IHC*	5
Non-Small Cell Lung Cancer (NSCLC) ROS1 FISH*	5
Non-Small Cell Lung Cancer (NSCLC) ROS1 IHC*	5
NPM1 Mutation Status	10
NT-proBNP	6, 18, 19
NTRK fusions*	15

O

Oncogenetics	14
Oncology	11
Osteogenesis Imperfecta (OI)	15
Other Programmes (Blood Coagulation)	8
Other Services Supplementary to EQA (BTLP)	9

Index

P			
Paediatric Acute Leukaemia Translocations	10	Preimplantation genetic testing (PGT) of Blastomere (FISH)	16
Paediatric Bilirubin	6	Preimplantation genetic testing (PGT) of Polar Body	16
Paraneoplastic Antibodies	11	Prenatal constitutional Copy Number Variant (CNV) detection	16
Parasite Serology	13	Prenatal karyotyping	16
Paroxysmal Nocturnal Haemoglobinuria	10	Prenatal Testing	16
Parvovirus B19 and Rubella Serology	13	Pre-Transfusion Testing (PTT)	9
Pathogenicity of germline postnatal copy number variants (CNV) (Classification Only)*	17	Primary Immunodeficiency disorders (PID)	15
Pathogenicity of germline sequence variants (Classification & Interpretation)	17	Procalcitonin	11, 18
Pathogenicity of germline sequence variants (Classification only)	17	Prostate cancer (HRR testing)*	16
Pathogenicity of prenatal copy number variants (Classification only)*	17	Prostate Specific Antigen (PSA)	11
Pathogenicity of somatic sequence variants (Classification only)*	17	Protein C Antigen and Activity Assay	8
Peptide I	7	Protein S Activity Assay	8
Peptide II	7	Protein S Total and Free Antigen Assay	8
Phospholipase A2 Receptor Antibodies (PLA2R)	11	Prothrombin Time (PT)/INR (Venous/ Capillary methods)	8
Phospholipid Antibodies	11	Prothrombin Time for Diagnosis (PT/ Diagnostic) (PTD)	8, 18
Pilot Schemes (BTLP)	9	PTH, ACTH and Calcitonin	7
PIVKA-II (undercarboxylated prothrombin) at endogenous concentrations in human serum	9		
Placental Growth Factor (PLGF)	7	Q	
Plasma Viscosity	9, 18	Quantitative Amino Acids	6
Plasminogen Assay	8	Quantitative Factor VIII Inhibitor	8
POCT (Blood Coagulation)	8	R	
POCT D-dimer	8, 19	Rapid Prenatal Testing for common aneuploidies	16
Point of Care CRP	11, 18, 19	Recurrent miscarriage karyotyping	14
Point of Care D typing (POCTD)	9, 19	Red Cell Enzyme	9
Postnatal constitutional Copy Number Variant (CNV) detection	14	Red Cell Genotyping (RCG)	9
Post-Stem Cell Transplant Chimerism Monitoring	10	Renal Biopsy Pathology	5
Prediction of 5-Fluorouracil Toxicity (DPYD)*	15	Renal Disorders	15
Pre-eclampsia Markers*	7	Renal Tumours*	16
Pregnancy loss (G-banding)	16	Respiratory disorders	15
Pregnancy loss (Molecular methods)	16	Respiratory Rapid: RSV	13, 19
Pregnancy Testing	7, 19	Reticulocyte Count	9
Preimplantation Genetic Testing (PGT)	16	Rh and K Phenotyping	9
Preimplantation genetic testing (PGT) for aneuploidy	16	RhD typing	9
Preimplantation genetic testing (PGT) for chromosomal rearrangements	16	Rubella IgG Serology	13
Preimplantation Genetic Testing (PGT) for monogenic disorders	16	S	
		Sample Handling (Genomics)	16
		Sarcoma	16
		SARS-CoV-2 Antibody Detection	11, 18
		SARS-CoV-2 Antigen*	18
		SCID Molecular Newborn Screening (bloodspots)*	15

Index

S continued

Screening Tests (Blood Coagulation)	8, 18
Serum Indices (HIL)	6
Severe Developmental Delay*	14
Sex chromosome disorders karyotyping	14
SFlt-1	7
SFlt-1: PLGF ratio	7
Sickle Screening only	9
Skeletal Dysplasias	15
Specialist Techniques (Cellular Pathology Technique)	5
Specific Microbial Antibodies	11
Specific Proteins	6
Steroid Hormones	6
Sweat Testing	6
Syphilis Serology	13

T

Teaching for Blood and Faecal Parasites	13
Technical (Next Generation Sequencing)	16
Thrombin Time (TT)	8
Thromboelastometry and Thromboelastography	8, 19
Thyroglobulin	6
Thyroid Cancer*	16
Thyroid Hormones	6
Tissue Diagnostics (Cellular Pathology Technique)	5
Tissue inhibitor of metalloproteinase I (TIMP-I)	7
Tissue-i	14
Total IgE	11
Toxicology (TOX) and Therapeutic Drug Monitoring (TDM)	6
Toxoplasma Serology	13
Training, Assessment and Competency Tool (TACT)	9
Transmission Electron Microscopy (TEM)	5
Treatment & Monitoring Programmes (Covid-19)	18
Triple Negative Breast Cancer (TNBC) PD-L1 IHC*	5
Tryptase	11
Tumour Markers	7
Tumour Markers (CA Series)	11
Type III Procollagen Peptide (PIIINP)	7

U

Ultrasensitive C-Reactive Protein	11
Ultrasensitive PSA	11
Urinary Antigens	13, 19
Urinary Catecholamines & Metabolites	6
Urinary hCG (Qualitative and Quantitative)	7
Urine Chemistries	6
Urine Dipsticks	6, 19

V

Variant Classification (Genomics)	17
Variant Validation (Genomics)	17
Viral Gastroenteritis (also suitable for antigen testing)	13, 19
Virology	13
Virus identification	13
Vitamin Assays (Carotene, Vitamin A & E)	6
Vitamin D	6
Vitamin K1 at endogenous concentrations in human serum	9
Vitamin K1, 2, 3-epoxide at endogenous concentrations in human serum	9
Von Willebrand Factor Antigen: Assay	8
VWF:CB (collagen-binding) Assay	8
VWF:RCo (activity) Assay	8

W, X, Y & Z

X-Inactivation	15
Zinc, Copper, Aluminium, Selenium, Chromium and Cobalt in Serum	6

Current Participating Countries

Afghanistan	Falkland Islands	Lesotho	Reunion
Albania	Fiji	Liechtenstein	Romania
Angola	Finland	Lithuania	Russia
Argentina	France	Luxembourg	Rwanda
Armenia	French Polynesia	Macau	Saudi Arabia
Aruba	French Guiana	Madagascar	Senegal
Australia	Gambia	Malawi	Serbia
Austria	Georgia	Malaysia	Sierra Leone
Azerbaijan	Germany	Martinique	Singapore
Bangladesh	Ghana	Mali	Sint Maarten
Belarus	Gibraltar	Malta	Slovak Republic
Belgium	Greece	Mauritius	Slovenia
Benin	Greenland	Mexico	South Africa
Bolivia	Guadeloupe	Monaco	Spain
Bosnia and Herzegovina	Guatemala	Mongolia	Sri Lanka
Botswana	Guinea	Montenegro	Sudan
Brazil	Haiti	Morocco	Swaziland
Bulgaria	Honduras	Mozambique	Sweden
Burkina Faso	Hong Kong	Namibia	Switzerland
Cambodia	Hungary	Nepal	Taiwan
Cameroon	Iceland	Netherlands	Tajikistan
Canada	India	New Caledonia	Tanzania
Central Africa Republic	Indonesia	New Zealand	TCHAD
Chile	Iran	Nicaragua	Thailand
China	Iraq	Niger	Togo
Colombia	Ireland	Nigeria	Tunisia
Congo, Democratic Republic	Israel	Norway	Turkey
Costa Rica	Italy	Oman	Turkmenistan
Cote d'Ivoire	Jamaica	Pakistan	Uganda
Croatia	Japan	Panama	UK
Curacao	Jordan	Papua New Guinea	Ukraine
Cyprus	Kazakhstan	Paraguay	United Arab Emirates
Czech Republic	Kenya	Peru	Uruguay
Denmark	Kingdom of Bahrain	Philippines	USA
Dominican Republic	Kosovo	Poland	Uzbekistan
Ecuador	Kuwait	Portugal	Venezuela
Egypt	Kyrgyzstan	Qatar	Vietnam
El Salvador	Lao PDR	Republic of Korea	Yemen
Estonia	Latvia	Republic of Macedonia	Zambia
Ethiopia	Lebanon	Republic of Moldova	Zimbabwe

UK NEQAS

Contact Information

Centre	Telephone	Email
Birmingham Quality	+44 (0) 121 414 7300	birminghamquality@uhb.nhs.uk
Blood Coagulation	+44 (0) 114 267 3300	neqas@coageqa.org.uk
Blood Transfusion Laboratory Practice (BTLP)	+44 (0) 1923 217 933	btlp@ukneqas.org.uk
Cardiac Markers	+44 (0) 141 440 2888	info@ukneqas-cm.org.uk
Cellular Pathology Technique	+44 (0) 191 816 1030	cpt@ukneqas.org.uk
Edinburgh Peptide Hormones	+44 (0) 131 242 6885	ukneqas@ed.ac.uk
Genomics	Oxford: +44 (0) 1865 857 644 Edinburgh: +44 (0) 131 242 6898	info@genqa.org
Guildford Peptide Hormones	+44 (0) 1483 571 122 ext. 3611	rsch.peptideeqa@nhs.net
Haematology	+44 (0) 1923 217 878	haem@ukneqas.org.uk
Head and Neck Pathology	+44 (0) 121 371 5723	neckpath@ukneqas.org.uk
Histocompatibility and Immunogenetics	+44 (0) 1443 622 185	handi@ukneqas.org.uk
Immunocytochemistry & In-Situ Hybridisation	+44 (0) 208 187 9174	info@ukneqasiccish.org
Immunology, Immunochemistry & Allergy	+44 (0) 114 271 5715	immunology@ukneqas.org.uk
Leucocyte Immunophenotyping	+44 (0) 114 267 3600	admin@ukneqasli.co.uk
Microbiology	+44 (0) 208 905 9890	organiser@ukneqasmicro.org.uk
Neuropathology	+44 (0) 1865 234 904	neuropath@ukneqas.org.uk
Parasitology	+44 (0) 203 908 1371	parasite@ukneqas.org.uk
Reproductive Science	+44 (0) 161 276 6437	repscience@ukneqas.org.uk
Trace Elements	+44 (0) 1483 571 122 ext. 3611	rsc-tr.Guildford-EQA@nhs.net
Vitamin K	+44 (0) 207 188 6815	keqas@ukneqas.org.uk

UK NEQAS

International Quality Expertise

UK NEQAS Central Office
PO BOX 401
Sheffield S5 7YZ

Tel : +44 (0) 114 261 1689

centraloffice@ukneqas.org
www.ukneqas.org.uk

